NO20080024L - Sammensetninger og metoder for behandling av syklus-relaterte symptomer - Google Patents

Sammensetninger og metoder for behandling av syklus-relaterte symptomer

Info

Publication number
NO20080024L
NO20080024L NO20080024A NO20080024A NO20080024L NO 20080024 L NO20080024 L NO 20080024L NO 20080024 A NO20080024 A NO 20080024A NO 20080024 A NO20080024 A NO 20080024A NO 20080024 L NO20080024 L NO 20080024L
Authority
NO
Norway
Prior art keywords
methods
compositions
related symptoms
treating cycle
cycle
Prior art date
Application number
NO20080024A
Other languages
English (en)
Inventor
Ginger Dale Constantine
Gary Sondermann Grubb
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20080024L publication Critical patent/NO20080024L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Metoder er gitt for behandling av syklusrelaterte symptomer ved administrering av minst ett progestin og minst ett østrogen til et kvinnelig individ.
NO20080024A 2005-06-28 2008-01-03 Sammensetninger og metoder for behandling av syklus-relaterte symptomer NO20080024L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69507705P 2005-06-28 2005-06-28
PCT/US2006/025449 WO2007002862A2 (en) 2005-06-28 2006-06-27 Compositions and methods for treatment of cycle-related symptoms

Publications (1)

Publication Number Publication Date
NO20080024L true NO20080024L (no) 2008-03-27

Family

ID=37440889

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080024A NO20080024L (no) 2005-06-28 2008-01-03 Sammensetninger og metoder for behandling av syklus-relaterte symptomer

Country Status (19)

Country Link
US (1) US20070009594A1 (no)
EP (1) EP1896037A2 (no)
JP (1) JP2008544989A (no)
KR (1) KR20080017061A (no)
CN (1) CN101252937A (no)
AR (1) AR054525A1 (no)
AU (1) AU2006263542A1 (no)
BR (1) BRPI0613021A2 (no)
CA (1) CA2612885A1 (no)
CR (1) CR9601A (no)
EC (1) ECSP078066A (no)
GT (1) GT200600280A (no)
IL (1) IL188237A0 (no)
MX (1) MX2007016364A (no)
NO (1) NO20080024L (no)
PE (1) PE20070327A1 (no)
RU (1) RU2007148080A (no)
TW (1) TW200726473A (no)
WO (1) WO2007002862A2 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
DE102007011486A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Arzneimittel umfassend wenigstens ein Gestagen
US20120263784A1 (en) * 2009-10-12 2012-10-18 Lyka Labs Limited Emergency contraceptive
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
WO2012129812A1 (zh) * 2011-03-31 2012-10-04 深圳市康泰尔电子有限公司 电子香烟
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
DE102019115343A1 (de) * 2019-06-06 2020-12-10 EVESTRA GmbH Vaginalring für die hormonelle Kontrazeption

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291014A (en) * 1979-01-11 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing estradiol diacetate
US4438139A (en) * 1979-08-14 1984-03-20 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing estrogens
JPS60174716A (ja) * 1984-02-21 1985-09-09 Yamanouchi Pharmaceut Co Ltd パツチ剤
US4752478A (en) * 1984-12-17 1988-06-21 Merck & Co., Inc. Transdermal system for timolol
DE19705229C2 (de) * 1997-02-12 1999-04-15 Hesch Rolf Dieter Prof Dr Med Verwendung von drei Hormonkomponenten zur hormonalen Kontrazeption zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
EP2305229A1 (en) * 2001-12-05 2011-04-06 Teva Women's Health, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
EP1648382A4 (en) * 2003-07-16 2009-09-16 Duramed Pharmaceuticals Inc HORMONE TREATMENT METHODS USING CONTRACEPTIVE DOSAGES WITH CONTINUOUS ADMINISTRATION OF ESTROGENES
WO2005117898A1 (en) * 2004-05-26 2005-12-15 Wyeth Compositions and methods for treatment of premenstrual dysphoric disorder

Also Published As

Publication number Publication date
IL188237A0 (en) 2008-06-05
ECSP078066A (es) 2008-01-23
KR20080017061A (ko) 2008-02-25
PE20070327A1 (es) 2007-05-04
RU2007148080A (ru) 2009-08-10
AU2006263542A1 (en) 2007-01-04
CA2612885A1 (en) 2007-01-04
EP1896037A2 (en) 2008-03-12
MX2007016364A (es) 2008-03-05
BRPI0613021A2 (pt) 2010-12-14
TW200726473A (en) 2007-07-16
JP2008544989A (ja) 2008-12-11
WO2007002862A2 (en) 2007-01-04
CN101252937A (zh) 2008-08-27
CR9601A (es) 2008-05-05
US20070009594A1 (en) 2007-01-11
AR054525A1 (es) 2007-06-27
WO2007002862A3 (en) 2007-02-22
GT200600280A (es) 2007-02-26

Similar Documents

Publication Publication Date Title
NO20080024L (no) Sammensetninger og metoder for behandling av syklus-relaterte symptomer
UA100250C2 (uk) Інгібітори реплікації вірусу імунодефіциту людини
UA92355C2 (en) urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS
DK1836169T3 (da) Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser
DK2023918T3 (da) Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
NZ594746A (en) Inhibitors of iap
SG157365A1 (en) Compositions and methods for treating neoplastic diseases
EA200870385A1 (ru) Ингибирование токсичности альфа-синуклеина
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
HK1113352A1 (en) Chemical compounds
HK1114375A1 (en) Chemical compounds
DK1893196T3 (da) Diarylhydantoin-forbindelse
DE602007010664D1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
NO20091576L (no) Sammensetninger av TRL-ligander og antiviraler
TW200738657A (en) Thiazole compounds and methods of use
GEP20125565B (en) Lactam compounds and their pharmaceutical use
WO2010059004A3 (ko) 스네일-p53 간의 결합을 저해하는 화합물 및 이를 유효성분으로 함유하는 암질환 치료제
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
MX2012007032A (es) Composiciones organicas para tratar las enfermedades relacionadas con hsf1.
BRPI0720050A2 (pt) 6-oxo-1,6-diidropirimidin-2-ilas no tratamento de doenças proliferativas
TW200738611A (en) 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
EP2077719A4 (en) BETA-SECRETASE PIPERIDINE AND PYRROLIDINE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
DK1814879T3 (da) Derivater af 4,7-dioxobenzothiazol-2-caboxamider, fremgangsmåde til fremstilling deraf og terapeutiske anvendelser af samme
WO2008002614A3 (en) Pseudoazulenyl nitrones

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application